In this issue

- EDITORIAL
  - Message from the eNews Editor 4

- THE VOICE OF IFCC
  - IFCC President’s Message – September 2022 5
  - Call for nominations for IFCC Regional Federation Representatives 2024-2026 6
  - Call for nominations for Corporate Representative position within the IFCC EB 2024-2026 7
  - Call for nominations for the election of the IFCC Secretary and Treasurer 8
  - The IFCC WorldLab Seoul 2022 report 9
  - IFCC Professional Exchange Programme: call for hosting labs 13
  - News from the IFCC Committee on Point-Of-Care Testing 14

- IFCC CELEBRATES 70 YEARS
  - Interview with Prof. Michael Neumaier 16
CONTRIBUTE TO IFCC eNews

- The relevance of measuring in clinical laboratory processes: experience of a clinical pathology service in a middle-income country

NEWS FROM REGIONAL FEDERATIONS AND MEMBER SOCIETIES

- Dr. Luis García de Guadiana awarded for best clinical research article published in 2021 in the European Journal of Clinical Investigation

- New EFLM functional units under the EFLM Science Committee

IFCC WELCOMES NEW CORPORATE MEMBERS

- Quality Academics - Mexico

- ARKRAY Inc.

- Jiangsu BioPerfectus Technologies Co., Ltd.

IFCC'S CALENDAR OF CONGRESSES, CONFERENCES & EVENTS

- Calendar of IFCC Congresses/Conferences and Regional Federations' Congresses

- Other events with IFCC auspices
Dear colleagues,

With the first raindrops the summer is gone... As the summer is still here in Greece and especially in the islands, it is a great idea to join us in Crete for the IFCC-GSCC Joint Symposium on October 2nd.

In the meantime, full of images of sunsets, seasides or green mountains, we are back to work in our labs. It is a different time of the year!

IFCC, our international society that gives us visibility as lab people and shows our importance all over the world, is planning lots of events for this fall. The most important event is the IFCC General Conference in Brussels, where we will celebrate the 70-year anniversary of IFCC. Our President, Prof. Adeli invites us to this wonderful event in his message.

In this issue of the eNews you will find Ms. Helen Martin's very interesting description of the WorldLab in Seoul, with a lot of information about the city, the congress, the people, the atmosphere.

In this issue, an interview with Prof. Michael Neumaier on the 70 years' anniversary and his long experience in his positions in IFCC offers a great view of IFCC life over time.

News from the committees and working groups and corporate members are completing this issue.

With my best wishes for a wonderful fall!

Katherina Psarra
Greetings to everyone in the IFCC family! I hope you have all had a wonderful summer. Here at IFCC, we are looking forward to a very productive Fall season. There are many upcoming events planned this quarter as we come out of the COVID-19 pandemic. These include the AFCB Congress in Broummana, Lebanon (September 8-10), IFCC-GSCC Joint Symposium in Crete, Greece (October 2), as well as several other meetings, workshops, and live webinars. For more information, visit the IFCC website. I look forward to seeing our IFCC community at these important events!

This Fall, IFCC will also be hosting the General Conference for invited IFCC Officers in Brussels, Belgium from October 28-31, 2022. Members of Committees and Taskforces as well as Presidents of National Societies and Regional Federations have been invited and are encouraged to attend. This year’s meeting will present a special opportunity to celebrate the 70th Anniversary of IFCC, recognizing 70 years of global leadership in laboratory medicine and celebrating our contributions to advancing excellence in laboratory medicine for better healthcare worldwide.

This occasion will be commemorated throughout the meeting with special events, including a social dinner with live jazz music. Alongside updates from IFCC functional groups including new IFCC Task Forces, several special symposia are planned including: presentations from IFCC Past Presidents, presentations from all six Regional Federation Presidents, a Special Symposium on the Central Role of Lab Medicine in Patient Care & Public Health with expert presentations from AACC, WHO, and others, as well as an Industry Forum by diagnostic industry leaders on the Future of IVD over the Next Decade. Brussels will set the perfect backdrop for these activities as a truly global city, often referred to as the “capital of Europe”.

In addition to upcoming events, the IFCC Task Force on Outcome Studies in Laboratory Medicine (TF-OSLM) is developing a funded research program for investigators in clinical labs, hospitals, and other institutions located around the world to conduct new retrospective and prospective research with outcomes that assess the value of laboratory medicine in healthcare overall. A call for proposals has been sent out, seeking research proposals for studies evaluating the impact of laboratory testing on health outcomes. These activities will fulfill the strategic objectives set out by TF-OSLM, which include promotion of directed research evaluating the role of laboratory medicine on clinical outcomes as well as building awareness and understanding with regard to the critical role laboratory medicine plays in healthcare outcomes.

Looking forward to a very productive fall season for IFCC member societies, national federations, and colleagues from around the world. As always, feel free to email me at president@ifcc.org with your feedback, questions, or concerns.

Cheers, Khosrow 😊
The IFCC Nominations Committee is announcing the call for nominations for Regional Federation representative members of the IFCC Executive Board for service from January 1, 2024, to December 31, 2026. Each of the six IFCC Regional Federations (AFCB, AFCC, APFCB, EFLM, COLABIOCLI, and NAFCC), will be represented at the Executive Board by one representative of its Region.

This election is under the responsibility of the IFCC Nominations Committee according to the last version of the IFCC statutes and rules. Any full member society in good standing may nominate an individual to serve in the IFCC Executive Board representing his/her Regional Federation.

In order to be an effective representative for the Regional Federation each elected individual should be a member of the IFCC Executive Committee throughout the three-year period 2024-2026. It is for the Regional Executive Committee/Board to determine how this may be achieved, whilst respecting the right of any IFCC Full Member society to submit a nomination. The candidate should have a thorough knowledge of the functioning of his/her Region and must ensure that he/she is able to work in harmony with the Regional Executive Committee/Board and the IFCC Regional membership.

TIMETABLE:

- **1st September – 30th November 2022**
  The call for nominations for the Regional Representatives will be sent to IFCC Full Member Societies and to the Regional Federation Executive Committees/Boards. The closing date for nominations is 30th November 2022.

- **1st – 31st December 2022**
  The Nominations Committee will consult with the respective Regional Executive Committee/Board to determine the eligibility of each Regional Candidate. The IFCC Office then sets the slate for the candidates for each Region.

- **1st – 31st January 2023**
  Slate of candidates is distributed widely throughout IFCC.

- **1st – 28th February 2023**
  Electronic Ballot - The Electorate will be the IFCC Full Members in each Region. The ballot will take place even if there is only a single nomination. The election will be arranged by the IFCC Office using the independent electronic voting system employed by IFCC. The only exception is the “North American Federation of Clinical Chemistry and Laboratory Medicine-NAFCC”; for this specific case, being only two IFCC Full Members forming NAFCC, confirmation in writing, by both Full Member societies supporting the single valid nominee, will remove the need for electronic voting.

- **By 31st March 2023**
  Announcement of elected Regional Representatives.

- **May 2023**
  The elected EB Members for 2024 – 2026 will be presented at the IFCC Council in Rome.
The IFCC Nominations Committee is announcing the call for nominations of the Corporate Member Representative for service on the Executive Board (EB) from January 1, 2024, to December 31, 2026.

Corporate Members are important partners for IFCC, making a valuable contribution to its scientific, educational and professional activities. The election of the Corporate Member Representative to the EB is an essential component of the operational and strategic management of the Federation, and its influence in the global field of laboratory medicine.

TIMETABLE FOR THE ELECTION OF THE CORPORATE REPRESENTATIVE:

- **1st September - 30th November 2022:**
  Call for nominations

- **1st - 31st December 2022:**
  Nominations Committee determines the eligibility of each candidate and sets the slate for the candidates for time in office 2024-2026

- **1st - 31st January 2023:**
  Slate of candidates is distributed to Corporate Members

- **1st - 28th February 2023:**
  Electronic Ballot by Corporate Members

- **By 31st March 2023:**
  Result communicated to candidates

- **May 2023:**
  Successful candidate presented to the IFCC Council in Rome

NOMINATION PROCEDURE:

- **Nominations** must be sent electronically to the IFCC office ([ifcc@ifcc.org](mailto:ifcc@ifcc.org)) **by 30th November.**

- **Consent from the applicant’s employer** (who must be an IFCC Corporate Member in good standing), must also be provided.

- **Nominees are invited to include in the application form** a short position statement.
The IFCC Nominations Committee is announcing the schedule for the election of the next IFCC Secretary and Treasurer who will serve on the Executive Board (EB) from January 1st, 2024 to December 31st, 2026.

IFCC Full Member Societies are invited to nominate appropriate candidates for these two positions on the EB. The election to the IFCC EB is a major step for the operational and strategic management of the Federation based on global partnership to strengthen the IFCC community. The EB team should develop a common vision based on a federal approach, which respects the diversity of cultures.

We invite you to propose candidates with a strong work ethic and vision who will commit to the Federation to assure a sustainable IFCC future, in a changing health care environment.

- **1st July – 30th September 2022:**
  Call for nominations

- **1st - 31st October 2022:**
  Nominations Committee determines the eligibility of each candidate and sets the slate for the IFCC Secretary and Treasurer for time in office 2024-2026

- **1st November - 31st December 2022:**
  Slate of candidates is distributed widely throughout IFCC

- **1st - 31st January 2023:**
  Electronic ballot

- **By 28th February 2023:**
  Results announced
The 24th International WorldLab Congress of the IFCC and 16th Congress of the Asia-Pacific Federation for Clinical Biochemistry and Laboratory Medicine (APFCB) was hosted by the Korean Society for Clinical Chemistry (KSCC) in the vibrant and beautiful city of Seoul, at once a bustling mecca of technology and skyscrapers and an oasis of tranquil gardens and Buddhist Temples and Palaces. Postponed due to the Covid pandemic from its original dates in 2020, the 24th IFCC WorldLab was rescheduled to January 2021 and again, finally, to 26-30th June 2022; this later time opened the wonderful opportunity to combine WorldLab for the first time with the APFCB Congress.

Laboratory Medicine is fundamental for optimal healthcare and laboratory professionals worldwide strive to provide high quality and cost-efficient service to their communities. Hence the Congress theme of Value-Based Laboratory Medicine was most appropriate and provided delegates with the opportunity to meet and be informed by experts in this area from around the world, enabling sharing of knowledge and facilitating improved health outcomes. Following the opening ceremony with its welcome addresses from IFCC President Khosrow Adeli, APFCB Vice-President Endang Hoyaranda and KSCC Congress President Won-Ki Min and entertaining and thought-provoking lecture entitled “Almighty Google knows everything about you” Congress delegates enjoyed a welcome cocktail banquet, for many the first opportunity in over two years to meet with international colleagues and friends, a truly welcome and joyous evening.

The scientific program flowed over the next three and a half days with four plenary lectures addressing the challenges of “Maximizing the value of laboratory medicine in Korea”, “Adding clinical utility to laboratory reports” as well as state of the art developments “Pharmacogenomics from discovery to clinic” and “Next Generation Sequencing analysis of genetic diseases”. Twenty-eight symposia, including five provided by IFCC and three by APFCB, provided expert insights into current challenges and opportunities such as utilization management of laboratory tests, using big data to improve healthcare, applications of advanced mobile web technology and laboratory information system technology. Advances in laboratory aspects of major disease burdens worldwide such as kidney disease, diabetes and sepsis were shared as well as educational sessions covering essential fundamentals such as standardization, harmonization, traceability, method assessment and quality control. In addition, many diagnostic companies provided workshops.

The exhibition space housed thirty-eight diagnostic company booths each eager to share information regarding their latest tests and equipment. An interesting initiative by the organisers was that, for the first time at an IFCC meeting, posters were presented electronically within the exhibition space.

While the congress offered the opportunity of virtual participation, a positive and valuable development arising from the pandemic and one which I believe is likely to persist into the future, for those who could participate face-to-face the 24th IFCC and 16th APFCB Congress in Seoul was a worthwhile and memorable experience.
Prof. Khosrow Adeli, IFCC President, at the Congress Opening

The great group of Young Scientists attending the Congress and the IFCC FORUM for Young Scientists

Article continued on next page
The exhibition area of the Congress

Break and networking during the Congress

Article continued on next page
Dr. Helen Martin, APFCB Secretary, with one of the delegates

Korean delegation with Presidents and authorities
The IFCC is happy to announce a major expansion of the Professional Exchange Programme (PEP) and an increase in the number of awards to support training of young scientists and continuing education of other laboratory professionals at clinical laboratory centres and IVD facilities around the world.

To facilitate this endeavour and to help applicants find the most suitable hosting laboratory, we wish to develop a list of potential Hosting Laboratories.

Hosting Laboratories should ensure:

- Availability of ample scientific expertise to train a visiting scientist
- Availability of space and time to provide training
- Access to laboratory facilities and resources
- Access to lab scientists and lab managers/supervisors

If you are available to host a visiting Young Scientist, please fill in the form (Excel file format).

**DEADLINE: September 30, 2022**

For additional information on PSEP and PMEP, please visit:

The IFCC Committee on Point-of-Care Testing held their meeting in Seoul.

Located on the Han river that bisects the city, Seoul has a fascinating history and is home to King Sejong the Great (May 7, 1397–April 8, 1450) who ruled during the Joeson Kingdom (1392–1910), and is best known for promoting literacy. He invented hangul, the Korean alphabet and made it simpler than Chinese so that everyone had the ability to learn it easily.

His promotion of science and scholarly activities made it a fitting city to host the IFCC 24th WorldLab Conference.

Among the items discussed by the POCT Committee was establishing a “POCT Tool Kit” on the IFCC website to help individuals setting up POC testing services.

Furthermore, the committee will be presenting a webinar in January 2023, titled, “POCT: Developing Community Resilience”, with the following speakers and titles: Julie Shaw, “Real-life performance of rapid antigen tests for COVID-19”, Rajiv Erasmus, “How Point of Care Testing has leveraged Infectious Disease Management and Outcomes in Africa,” and Gerald Kost on, “The COVID-19 Spatial Care Path: Home, Community, and Emergency Diagnostic Portals.”

Finally an IFCC POCT Symposium is also planned in Pakistan in 2023.
All Balanced and Strong

**Small but strong**
The throughput is up to 200 tests/hour, and the throughput per unit area is 294 T/h/m². Compatible with all MAGLUMI® reagents with perfect compatibility (166 parameters).

**Convenient and efficient**
No-pause loading/unloading of reagents/samples/reaction cups without waiting or interrupting tests. Intuitive indicator lights make no need to check reagents and consumables frequently.

**Low failure rate and accurate result**
The single reaction cup can avoid light pollution and increase cuvette utilization, its integrated packaging can avoid the stuck of the cuvette, cuvette blockage and scratches.

**Cost-efficient and intelligent**
TEFLON-coated pipetting needle is equipped with independent washing unit to avoid carry-over (Small workload analyzer have higher consumable costs when using disposable Tips).

**Excellent performance**
The comprehensive advanced design of MAGLUMI® X3 ensures excellent performance, such as the latest intelligent washing technology and bidirectional temperature control measurement.

www.snibe.com | sales@snibe.com
With following interview, we present the fourth interview delineating the many outstanding achievements of the IFCC over the past decades, the enormous achievements, the many important milestones that have been accomplished contributing to the IFCC’s mission of “Advancing excellence in laboratory medicine for better healthcare worldwide”

IFCC is celebrating 70 years of its foundation and we are conducting interviews with prominent professionals and authorities, for this reason we want to know your valuable opinion on following topics.

Prof. Michael Neumaier is a German Clinical Chemist, Laboratory Physician and immunologist by training and a European Specialist in Laboratory Medicine (EU-SpLM). He has been appointed professor at the Universities of Hamburg and Heidelberg. Since 2002, he is the chair of Clinical Chemistry and director of the Institute for Clinical Chemistry and the central laboratories at the Medical Faculty Mannheim of Heidelberg University. He has served his university many years in various capacities including Dean of Studies and vice Dean, a position he will hold until 2023. Prof. Neumaier has been the Founding Director of the Mannheim Institute for Innate Immunosciences (MI3) and of the Mannheim Institute for intelligent Systems in Medicine (MIiSM).

Prof. Neumaier has served the German Society for Clinical Chemistry and Laboratory Medicine (DGKL) in the Executive Board and as DGKL President. By appointment of the German Medical Council (BÄK), he is a director of the national...
“External Quality Assessment in Laboratory Medicine” programs and a founding member of the German Gene Diagnostics Commission. From 2016 to 2021, he has been Executive Board member of the EFLM and served as EFLM President between 2018 and 2019. Over the years until today, Prof. Neumaier has contributed to several working groups, task forces and committees in IFCC.

His research interests are in molecular diagnostics of malignant disease for early detection of cancer and therapy resistance, the molecular immunology of the innate immune system and preanalytical stability and quality of biomolecular markers. He is engaged in establishing and validating digitalization strategies for improved laboratory diagnostics and preventive medicine. His scientific oeuvre features approximately 240 mostly original research papers, a large body of scientific abstracts, book chapter contributions and numerous conference appearances.

1. How has IFCC helped scientific organizations in these 70 years of its foundation, especially those in which you have been president, director or member, such as: EFLM, DGKL, BAK, EQA, etc.

There are many answers to this important question, and all of them show that IFCC has provided great value to the field of laboratory diagnostics since her inception. IFCC has managed to bring together national member societies with very different backgrounds of various health care ecosystems. By doing so, the IFCC has continuously generated enthusiasm among like-minded laboratory specialists of different professional backgrounds to contribute their skills in the various causes. Everyone who has been serving in IFCC´s active groups and committees has – in my opinion - experienced that IFCC stands for progress in laboratory diagnostic affairs, and the lively structure of the different IFCC divisions bears witness to this. In essence, this concept carries well for 70 years and has grown the organization since the beginnings. I personally go back only 35 years as clinical chemist and laboratory physician in different capacities, and from my experience, IFCC always has been a beacon of orientation, guidance and professional and scientific exchange. For example, the German DGKL and her EQA organization has been proud to contribute to the standardization of methods and quality management activities within IFCC and has benefitted from the international collaborations in important groups like the JCTLM, Molecular Diagnostics and others. During my time in the EFLM, we have seen IFCC governing structures opening to the 6 Regional Federations allowing them to directly participate in the internal discussions and decision-making of the EB. To me, that demonstrates a healthy concept. Furthermore, I really appreciate IFCC´s sustained activities to support emerging countries in their efforts to advance their diagnostic capabilities, make their clinical laboratories more attractive for young scientists and form networks of mutual support, something that we were able to forward very successfully in EFLM starting under Sverre Sandberg´ś Presidency and coming to full fruition under my successor Ana-Maria Simundic, who has been very successful in this.

Article continued on next page
2. In these 70 years, what do you consider has been the highlight of IFCC in laboratory medicine?

To single out one achievement is difficult. IFCC has been extremely successful in her efforts to harmonize laboratory diagnostics, standardize procedures and methods and provide frameworks for sophisticated and comprehensive quality management systems and procedures. While high-quality laboratory results are often being taken for granted in the every-day medical routines, we should appreciate that the underlying ground-breaking achievements and concepts continue to carry and be relevant in today’s increasingly rapid analytical developments.

While I was in the EB of EFLM, IFCC launched, under President Maurizio Ferrari, the Emerging Technology Division (ETD), a move much discussed at the time. Looking at the increasingly rapid developments in technology – not only in analytical sectors, but particular in data science, data integration, connectivity and patient orientation – I believe that Laboratory Medicine can have a great future, if we manage timely responses to new scientific and diagnostic challenges in the health care sector. In my opinion, a dedicated division to identify new disruptive areas that are relevant for us, is a highlight and should be helpful for the development of our field.

3. How do you see the future of IFCC in the global context of our profession, for example in the EMB Committee, Clinical Molecular Biology Curriculum, of which you were Chair?

Two answers: The pandemic has shown how very efficient laboratory diagnostics can be, and how international collaborations are efficiently channeled through an organization like IFCC. Nobody should forget the contributions that countless laboratories all over the world have provided to identify and contain SARS-CoV2 infections. Personally, I think we should take this opportunity to discuss how to further increase the visibility of the laboratory and future diagnostic strategies particularly in scenarios of disease distribution through mobile societies. Close collaborations between national societies and Regional Federations may effectively tackle regional health challenges from the perspective of the medical laboratory. For example, EFLM and our friends in the AFCB have initiated the task force “Laboratory for Mobile societies” (LM4MS), and we were very happy about the endorsement of IFCC by President Adeli on our first regional EFLM/AFCB conference in 2021.

Furthermore, while Laboratory Medicine will continue to provide important local medical services, the mobility of societies will grow. New strategies to provide laboratory diagnostics will emerge through new technologies together with increasing access to health services. In IFCC, we need to develop concepts to respond to the future challenge of changing occupational profiles that will be more driven by data processing and management for improved clinical decision support. Our programs for education and continuous professional development need to reflect these developments, bringing me to the last point of
this argument: A big catalyzer for a successful future Laboratory Medicine will be engaged generations of young laboratory specialists. With specific reference to your question: I have gained the experience over the years in C-CMBC and other IFCC working groups, but also in discussions with young colleagues during my travels for EFLM that there is a great interest and appreciation of young scientists for mentoring. There is a great openness and curiosity of young individuals to learn and improve their knowledge, for which they were willing to travel quite some distances in order to participate in classes e.g. in C-CMBC.

4. A short message for all the great community that we are part of IFCC, in these 70 years of foundation

The 70 years of IFCC have been an exceptional success story for our profession and have laid a strong foundation both in analytics and with respect to our togetherness. Considering the increased potentials at hand, Clinical Chemistry and Laboratory Medicine will have a bright future in line with an old, but unabatedly important quote from Franz Volhard, a famous German physician in the early 20th century: “Before the therapy, the gods have put diagnosis”.

---

**News from the IFCC Website**

**eJIFCC Vol 33 n°2 - 2022**

eJIFCC Vol 33 n°2 is now available!

In this issue: Current laboratory aspects of COVID-19. Dr Béla Nagy, Guest Editor of this issue writes: “At the time of writing this foreword for the “COVID-19” thematic issue of the eJIFCC, over half a billion Coronavirus Disease 2019 (COVID-19) positive cases and more than 6.3 million COVID-19 related deaths have been recorded worldwide emphasizing the global impact of this pandemic.

We have already witnessed initial waves of the infection, and the vaccination campaigns in most countries have topped the near maximum number of immunized individuals, who opted to receive at least one dose of vaccine. On the other hand, we cannot predict recurrence of dramatic increases in the number of new (severe) cases in the future.

This current thematic issue of the eJIFCC is constituted by a series of manuscripts submitted from various parts of the world and provides an overview on various laboratory aspects of COVID-19.

Read more
21-25 May
WORLDLAB · EUROMEDLAB
ROMA 2023

25TH INTERNATIONAL CONGRESS OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE

25TH EUROPEAN CONGRESS OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE

55TH CONGRESS OF THE ITALIAN SOCIETY OF CLINICAL BIOCHEMISTRY AND CLINICAL MOLECULAR BIOLOGY

ORGANISING SECRETARIAT
Via Carlo Farini 81 - 20159 Milano (Italy)
Phone: +39 02 66802323
E-mail: info@2023roma.org
Don’t miss next IFCC complimentary Webinar
21st September, 2022
“Challenges in laboratory diagnosis of endocrine diseases”

Register here
The relevance of measuring in clinical laboratory processes:
experience of a clinical pathology service in a middle-income country

The World Health Organization defines quality as “Ensuring that each patient receives the most appropriate set of diagnostic and therapeutic services to achieve optimal health care, taking into account all the factors and knowledge of the patient and the service” (1). This definition gives a patient-oriented external user satisfaction approach, since a good result indirectly measures the process.

The word quality comes from the Latin “Qualitas” which is in turn derived from the Greek “Kalos” which has several meanings that revolve in relation to a quality of an aspect such as: the good, the honest, the beautiful, the noble, pleasure and happiness (2).

It could be inferred that the described qualities of the Greek «Kalos» are reflected in the patients who received quality care. However, it is necessary that these benefits of quality are also reflected in Laboratory Medicine professionals, who are the most important component of the process «Quality must be reflected in the internal and external user».

From this concept of quality derive its components, characteristics and other definitions such as «Quality Indicators», which are a measurement tool. In the last century William Thomson Kelvin mentioned «What is not defined cannot be measured. What is not measured cannot be improved. What is not improved, is always degraded». This sentence summarizes the impact of the importance and implementation of quality indicators in clinical laboratory processes (3).

In addition, do not forget that quality encompassing several fields, was landed in the health area by the hand of Avedis Donabedian, a pioneer in implementing the concept of quality in health systems who defines it as a “Property of medical care which can be obtained in various degrees» (4).

In Peru, there is a segmented and divided health system, where more than five health subsystems coexist in parallel. The majority being public health establishments, such as those of the Ministry of Health (MINSA), social security (EsSalud) and the armed and police forces (5).

Due to the high demand for health, public establishments manage the crisis «Putting out fires» where the unplanned and urgent are prioritized, perhaps displacing quality in clinical laboratories, added to the absence of a national program that promotes the accreditation of themselves (6.7).

It is at this point that laboratory medicine professionals must take the leading role, taking charge of quality in all phases of the total test process. To be certain that «The processes work well, it is not enough to have the perception of it; it is necessary to be able to measure them with indicators». By measuring them they can be improved and even compared with other laboratories and perhaps even with companies from other sectors of the industry, as is the case with Generic Benchmarking.

We describe an experience carried out in a social security hospital (200 beds on average), in a clinical laboratory, implementing a quality indicator and carrying out a productive analysis of the underlying causes of the problem.

Author: Angel Ampuero Romero
Resident in Clinical Pathology, Hospital III Suarez Angamos, Social Security, Peru

Editor: Luis Figueroa Montes
President of the Peruvian Medical Association of Clinical Pathology, Peru
This indicator was designed to measure the number of laboratory tests processed, the results of which are not displayed in the virtual medical record within the first 24 hours. At the same time, we sought to identify the causes that caused this delay. It was identified that in the pre-pre-analytical phase with the generation of laboratory requests by the treating physicians, they presented coding errors for the tests. This hindered a correct link from the hospital information system (HIS) with our laboratory information system (LIS), they had patient errors with double and even triple codes, having the same sample generated by different labels or having to extravasate other tubes. Bugs were fixed (8).

After several findings and in a quality meeting with all staff, it became clear that there is a need to implement more indicators and robust quality assurance. It should be noted that there are not enough human and financial resources in the public sector to be able to strengthen the entire test process with external quality assessment programs in the pre- and post-analytical components. Currently, most clinical laboratories focus on participating in external evaluation programs only in the analytical component. At present, we do not have laboratories in Peru accredited by the accrediting entity, with the ISO 15189 standard in the public sector (9).

My name is Angel Ampuero, I am a resident doctor in clinical pathology or also known as Laboratory Medicine, as a pathologist in training, I have been embracing this specialty for about two years and I realize how important it is to be able to measure what we do to improve processes and contribute to one of the pillars that sustains quality, which is «User satisfaction, both external and internal, and at the same time strengthening continuous improvement». I work at Hospital III Suárez Angamos and I hope to continue sharing my experience on this journey of the use of quality indicators in clinical laboratories.

Bibliographic references


5. La segmentación y la fragmentación de los servicios de salud [internet]. La salud desde la otra orilla. 2020 [citado el 11 de agosto de 2022]. Disponible en: https://saluddesdelatraorillas.com/2020/07/30/la-segmentacion-y-la-fragmentacion-de-los-servicios-de-salud/.


8. Ferro D, Fernanda M. Identificación de los errores que se cometen con más frecuencia en las diferentes fases de control del laboratorio clínico y el impacto en la seguridad del paciente. Pontificia Universidad Javeriana; 2012.

Learn about these success stories at UnivantsHCE.com

CONGRATULATIONS TO THE 2021 WINNERS

TOP TEAMS AROUND THE WORLD ARE ACHIEVING HEALTHCARE EXCELLENCE

RECOGNITION OF DISTINCTION
Medcan Health Management Inc.
UHCW NHS Trust and Warwick Medical School
King Abdulaziz Medical City – Jeddah

RECOGNITION OF ACHIEVEMENT
Hampshire Hospitals NHS Foundation Trust
Yantai Yuhuangding Hospital
UOC Medicina Trasfusionale AOOR Villa Sofia–Cervello
University Hospital Centre Zagreb & Polyclinic Avitum
King Hussein Cancer Foundation and Center
Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute
Zulekha Hospital Dubai

© 2022 Abbott. All rights reserved. ADD-139612-GBL-EN.
Dr. Luis García de Guadiana awarded for best clinical research article published in 2021 in the European Journal of Clinical Investigation

Within the context of the Congress of the European Society for Clinical Investigation Dr. Luis García de Guadiana receives award for best clinical research article published in 2021 in the European Journal of Clinical Investigation.

• Dr. Luis García de Guadiana Romualdo is a specialist in the Clinical Analysis Service of the Santa Lucía University Hospital (Cartagena) and a member of the Commission of Biological Magnitudes related to Medical Emergencies of the SEQCML.

• The award-winning article confirmed the high incidence of myocardial damage in COVID-19 patients.

• Troponin, measured in the first 24 hours of admission, was a useful tool for risk stratification, being the variable that contributed the most information to the final predictive model.

Madrid, June 17, 2022. During the recent Congress of the European Society for Clinical Investigation (ESCI), held in Bari from June 8 to 10, the article “Cardiac troponin and COVID-19 severity: Results from BIOCOVID study”, whose lead author is Dr. Luis García de Guadiana Romualdo, a specialist in the Clinical Analysis Service of the Santa Lucía University Hospital (Cartagena) and a member of the SEQCML Commission on Biological Magnitudes related to Medical Emergencies, received the award for best clinical research article published during the year 2021 in the European Journal of Clinical Investigation.

This article is one of three manuscripts published in international journals based on the data obtained in the BIOCOVID Multicenter Registry, an initiative of Laboratory Medicine professionals in Spain in which 32 hospitals from 9 autonomous communities participated and which received the patronage of the Spanish Society of Laboratory Medicine (SEQCML), among other societies. The main objective of this study was to evaluate the usefulness of a series of biochemical, hematometric, and coagulation markers, readily available in an emergency room laboratory, for risk stratification in COVID-19 patients who required hospital admission during the first wave of the pandemic in our country.

At the award ceremony, Dr. García de Guadiana Romualdo, in addition to thanking all the professionals involved in the study for their collaboration, explained that the objectives of this study were to assess the incidence of myocardial damage, defined by the concentration of troponin, in the study population, and to analyze the association of the damage with hospital mortality, as well as the possible influence of the use of cut-off points stratified by sex, as recommended by the IFCC (International Federation of Clinical Chemistry).

The study, which included 1,280 patients, confirmed the high incidence of myocardial damage in COVID-19 patients, which was higher in the subgroup of patients in which troponin T was used as an indicator. The use of cut-off points stratified by sex slightly increased the percentage of patients with myocardial damage. In addition, troponin, measured in the first 24 hours of admission, was a useful tool for risk stratification, being the variable that provided the most information to the final predictive model.
A very important and strong connexion exists between Nephrology and Laboratory Medicine. Indeed, renal diseases are not frequently symptomatic and Nephrologists rely most of the time on laboratory results to diagnose or monitor patients suffering from kidney diseases. Chronic Kidney Diseases (CKD) represent a significant burden for the society since it is estimated that around 10% of the adult population is affected. Hence, early diagnostic is of paramount importance and the detection (and quantification) of proteinuria and the estimation of the glomerular filtration rate (eGFR) are two strategic pillars of the KDIGO Guidelines. Yet, such Guidelines are often based on the assumption that results provided by clinical laboratories in the world are comparable. Important efforts of standardization have been made these last years, especially for serum creatinine and cystatin C. The field is however rapidly evolving and since the last inquiry in 2019 on the state of the art of laboratory clinical practice for the measurement of creatinine, cystatin C, the use of formulas and the measurement of GFR, new equations have been published and the interest in iohexol clearance for the measurement of GFR is increasing. Among the “new” equations, the CKD-EPI has proposed a “race-free” equation which is giving questionable result, especially from an European perspective. The European Kidney Function Consortium (EKFC) has also proposed new equations, based on European cohorts and on the usage of the “Q value”, defined as the median serum creatinine concentration in the population for which it is used. This equation is also valid from infants (>2 years) to the older old. Other European equations, like the Revised Lund-Malmö equation, are also available. Determination of iohexol clearance by HPLC-UV or LCMS-MS to measure the glomerular filtration rate is now recommended in various clinical settings, like in kidney donors, children undergoing chemotherapy, extreme body mass (low and high) and in any situation where creatinine or cystatin C are simply inaccurate to reflect kidney function.
The EFLM has initiated the creation of new Working Group on Artificial Intelligence (AI) under the Science Committee. This decision was made after the 3rd EFLM Strategic Conference on May 25-27, 2022, which dealt with this topic. AI is an important emerging technology, and in the future, it is likely that it will become integrated in many applications of laboratory medicine. Machine learning (ML), a methodological approach developed within the field of AI aimed at developing algorithms and models by which to make classifications and predictions based on large amounts of data, has gained a place in medicine and increasingly also in laboratory medicine for evaluating and interpreting biochemical data, although the application of ML in clinical laboratories still appears to be an unexpectedly slow process. Indeed, it has been proven that laboratory results were often used in AI application, but medical specialties like intensive care, infectiology and others have used these data more efficiently than laboratory medicine in 2020.

The difficulty is due to several factors, including the features of laboratory results such as the characterization of the laboratory data (unit of measurement/analytical principle/population description), cannot be reproducible in others setting, and, therefore the effort to develop tools based by ML appears as aesthetic operation of little significance.

Hence the necessity of creating a WG on this important topic. The EFLM has appointed Dr. Andrea Padoan from the University of Padova, Italy, as Chair of the WG.

The aims of the WG are:

1. to establish the guideline for the use of laboratory data in ML;
2. to evaluate the suitable application of the ML approach in laboratory medicine;
3. to publish studies where ML algorithms are applied to well characterized laboratory data collected from different European laboratories for meaningful and appropriate tasks;
4. to define interdisciplinary lectures and courses on AI topics.

For all these reasons, the EFLM Executive Board has decided to create the EFLM Task Group on Chronic Kidney Diseases which will aim at promoting the GFR measurement and the use of the European population-based equations in Europe. To know more: click here for the dedicated page in the EFLM website.

The EFLM Working Group on Artificial Intelligence

Reported by Michel Langlois
Chair of the EFLM Science Committee
Andrea Padoan
Chair of the EFLM Working Group on Artificial Intelligence
The EFLM has therefore recently launched a call for nominations to the National Societies, specifically indicating the requirements for the available positions as Full Member and Young Scientist-Full Member in this WG. The EFLM Science Committee will select among the nominated persons, authorities in the field of ML and AI in laboratory medicine, and not in general, and preferably experts who have personally built ML models or contributed to them. In addition, EFLM will also appoint some Experts/Consultants in this WG directly by invitation. The relevant IVD industry representatives will be invited also, as well as representatives from associations dealing with AI/ML such as European Association for Artificial Intelligence (EURAI). Moreover, to find additional authorities, in the call for nominations letter the National Societies are invited to indicate if there are local specialised Universities or Research Centers.

To know more: click here for the dedicated page in the EFLM website.

On demand content available for the IFCC Live Webinar on
“Importance of the Preanalytical Phase in different areas of the Laboratory" held on 7 September 2022

Date: September 7, 2022
Time: 11 AM (Eastern Standard), 5 PM (Central European), 11 PM (Beijing)

Para ver el evento en español haga Click aquí.
To access the recording in English Click here.
News from the IFCC Website

IFCC Calls for Nominations

Prof. Khosrow Adeli, President of IFCC, and of Prof. Päivi Laitinen, Chair of IFCC Congresses and Conferences Committee, are announcing a call for nominations for one Full Member position within the IFCC Congresses and Conferences Committee.

Replies should be sent to the IFCC Office (cardinale@ifcc.org) by 21 October 2022.

Prof. Philippe Gillery, Chair of IFCC Scientific Division, is announcing a call for nominations for two Full Member positions within the SD Executive Committee.

Replies should be sent to the IFCC Office (paola.bramati@ifcc.org) by 15 October 2022.

For any further information on nominations, please refer to your National or Corporate Representative. Information and contacts are available here.

News from the IFCC Website

Candidates for IFCC President-Elect position

The IFCC Nominations Committee has approved three valid nominations for the position of IFCC President-Elect.

The nominees may now be regarded as candidates for the role.

The candidates (in alphabetical surname order) are:

Professor Michael Neumaier - German Society for Clinical Chemistry and Laboratory Medicine (DGKL);
Professor Tomris Ozben - Turkish Biochemical Society (TBS);
Professor Tahir Pillay - South African Association for Clinical Biochemistry and Laboratory Medicine (SAACB).

Read more
IFCC WELCOMES THREE NEW CORPORATE MEMBERS

Quality Academics - Mexico

We are a company committed on the permanent education of the clinical laboratory personnel and blood banks in Latin America.

We seek to improve analytical quality, strengthen management systems and guarantee patient safety by bringing together experts from Latin America and all over the world.

We have a digital platform to offer on-demand academic programs such as diplomas, workshops, courses on topics related to analytical quality control in the medical lab such as six sigma, method validation and verification, management systems such as ISO 15189, patient safety, etc.

Website: http://quality-academics.com.mx/.

ARKRAY Inc.

Founded in 1960 in Kyoto, Japan, ARKRAY has been the world leader in the field of In Vitro Diagnostics (IVD) testing.

As a pioneer in HbA1c testing and urine testing, we developed and released its first fully automated HbA1c analyzer in 1981 and developed the world’s first automated analysis system for use with urine test strips in 1972. We currently provide comprehensive support to the medical field ranging from development, manufacturing, sales and servicing including diagnosis support tools such as software.

Willing to take on new challenges, we solve issues in the medical field and support the healthy livelihood of people around the world.

Website: www.arkray.co.jp/english/.
Since its founding in 2010, BioPerfectus (SSE:688399) has been dedicated to providing holistic molecular diagnostic solutions specializing in emerging infectious diseases for generations and generations to come.

We are leading the change by offering qRT PCR Kits, Nucleic Acid Extraction Systems, Automation Solutions, and Rapid Tests to laboratories, hospitals, institutions, and CDCs across the globe. As one of the leading global IVD suppliers, BioPerfectus is committed to delivering excellent services and products that meet the highest international quality and safety standards.

Our global presence enables us to build close relationships with our clients and leverage our expertise to support them worldwide.

To “embrace the world with health” has always been our mission. But that’s not where our mission ends. We are getting what we have learned, researched, and prepared for the subsequent emergency calls from infectious diseases and saving people’s lives. This is us; this is BioPerfectus.

See how we’re using diagnostics to save the world:

## IFCC'S CALENDAR OF CONGRESSES, CONFERENCES & EVENTS

### Calendar of IFCC Congresses/Conferences

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sep 21, 2022</td>
<td>Challenges in laboratory diagnosis of endocrine diseases</td>
<td>Live Webinar</td>
</tr>
<tr>
<td>Oct 2, 2022</td>
<td>IFCC-GSCC Joint Symposium: “Medical Test Performance should keep pace with Evolution in Science and Clinical Guidelines: state of play and challenges for CardioVascular Disease tests in this era of Precision Medicine”</td>
<td>Hybrid event, Creete, GR</td>
</tr>
<tr>
<td>Oct 5, 2022</td>
<td>Aspects of Newborn Screening</td>
<td>Live Webinar</td>
</tr>
<tr>
<td>Oct 19, 2022</td>
<td>From Data to Decisions: Data and Analytics Leadership in Clinical Laboratory Management</td>
<td>Live Webinar</td>
</tr>
<tr>
<td>Nov 9, 2022</td>
<td>Single Cell and Spatial Transcriptomics: clinical application</td>
<td>Live Webinar</td>
</tr>
<tr>
<td>Nov 23, 2022</td>
<td>The role of key laboratory tests in the investigation and management of metabolic bone disease</td>
<td>Live Webinar</td>
</tr>
</tbody>
</table>

*Calendar continued on next page*
<table>
<thead>
<tr>
<th>Date</th>
<th>Event Description</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dec 1, 2022</td>
<td>Developments in reference measurement systems for C-reactive protein and the importance of maintaining currently used clinical decision-making criteria - JCTLM in cooperation with CIRME</td>
<td>Sesto San Giovanni, Milano, Italy</td>
</tr>
<tr>
<td>May 21 - 25, 2023</td>
<td>XXV IFCC - EFLM WorldLab EuroMedLab - Rome 2023</td>
<td>Rome, IT</td>
</tr>
<tr>
<td>May 26 -30, 2024</td>
<td>XXVI IFCC WORLDLAB - Dubai 2024</td>
<td>Dubai, UAE</td>
</tr>
<tr>
<td>April 2024</td>
<td>XXVI COLABIOCLI 2024</td>
<td>Cartagena, CO</td>
</tr>
<tr>
<td>October 31 - Nov 3, 2024</td>
<td>APFCB 2024 Sydney</td>
<td>Sidney, AU</td>
</tr>
<tr>
<td>2025 Date TBA</td>
<td>XXVI IFCC-EFLM EUROMEDLAB 2025</td>
<td>Venue to be selected</td>
</tr>
<tr>
<td>2026 Date TBA</td>
<td>XXVII IFCC WORLDLAB 2026</td>
<td>Venue to be selected</td>
</tr>
</tbody>
</table>
## Other events with IFCC auspices

<table>
<thead>
<tr>
<th>Date</th>
<th>Event Description</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sept 21 - 23, 2022</td>
<td>2nd Edition of the OncoHub Conference</td>
<td>Hybrid event Poiana Brașov, RO</td>
</tr>
<tr>
<td>Sept 21 - 29, 2022</td>
<td>Training in biosafety aimed at the management of fungal strains</td>
<td>Quality Academics, online event</td>
</tr>
<tr>
<td>Sept 22 - 24, 2022</td>
<td>XVI Baltic Congress in Laboratory Medicine</td>
<td>Tallin, EE</td>
</tr>
<tr>
<td>Date</td>
<td>Event</td>
<td>Location</td>
</tr>
<tr>
<td>--------------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Sept 22 - 24, 2022</td>
<td>22èmes Journées Marocaines de Biologie Clinique</td>
<td>Casablanca, MA</td>
</tr>
<tr>
<td>Sept 28, 2022</td>
<td>International Conference on Laboratory Medicine &quot;Moving laboratory medicine beyond the pandemic: from disruptive technologies to innovation&quot;</td>
<td>Padua, IT</td>
</tr>
<tr>
<td>Sept 28 - Oct 1, 2022</td>
<td>10th Congress of the Croatian Society of Medical Biochemistry and Laboratory Medicine</td>
<td>Zagreb, HR</td>
</tr>
<tr>
<td>Sept 29 - Oct 2, 2022</td>
<td>XXXI World Congress of the World Association of Societies of Pathology and Laboratory Medicine (WASPaLM)</td>
<td>Punta del Este, UY</td>
</tr>
<tr>
<td>Sept 30, 2022</td>
<td>Cardiac Marker Dialogues</td>
<td>Glasgow, UK</td>
</tr>
<tr>
<td>Oct 2, 2022</td>
<td>International Conference on Immunoassay</td>
<td>Snibe Dubai, UAE</td>
</tr>
<tr>
<td>Oct 2 - 5, 2022</td>
<td>2nd AFCB-EFLM Conference Laboratory Medicine for Mobile Societies in the Mediterranean Area</td>
<td>Heraclion - Crete, GR</td>
</tr>
<tr>
<td>Oct 4 - 9, 2022</td>
<td>FEBS Advanced Course: 360-degree Lysosome; from structure to genomics, from function to disease-update</td>
<td>Izmir, TR</td>
</tr>
<tr>
<td>Oct 5 - 7, 2022</td>
<td>5emes Journées Francophones de Biologie Médicale (5e JFBM)</td>
<td>Hybrid event Saint Etienne, FR</td>
</tr>
<tr>
<td>Oct 12 - 14, 2022</td>
<td>XV Congreso Nacional de Laboratoristas Clínicos de Panamá</td>
<td>Panamá</td>
</tr>
<tr>
<td>Oct 13 - 14, 2022</td>
<td>Deutscher Kongress für Laboratoriumsmedizin 2022</td>
<td>Mannheim, DE</td>
</tr>
<tr>
<td>Oct 14 - 17, 2022</td>
<td>46th ISOBM Congress</td>
<td>Bled, SI</td>
</tr>
<tr>
<td>Oct 17 - 19, 2022</td>
<td>7th SIPMeL National Congress Laboratory Medicine: New Complexities and Future Strategies</td>
<td>Hybrid event Riva del Garda, IT</td>
</tr>
<tr>
<td>Oct 18 - 20, 2022</td>
<td>AACB 59th Annual Scientific Conference</td>
<td>Hybrid event Perth, AU</td>
</tr>
<tr>
<td>Oct 26 - Nov 15, 2022</td>
<td>How to write and publish: a good scientific &amp; professional article</td>
<td>Online event</td>
</tr>
</tbody>
</table>

Calendar continued on next page
<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oct 26 - 30, 2022</td>
<td>TBS International Biochemistry Congress 2022 &amp; 33rd National Biochemistry Congress organized by the Turkish Biochemical Society</td>
<td>Izmir, TR</td>
</tr>
<tr>
<td>Oct 28, 2022</td>
<td>International Conference on Immunoassay</td>
<td>Snibe Brussels, BE</td>
</tr>
<tr>
<td>Nov 7 - 9, 2022</td>
<td>XI Argentine Congress of Quality in the Clinical Laboratory (CALILAB2022)</td>
<td>Mar del Plata City, AR</td>
</tr>
<tr>
<td>Nov 11 - 14, 2022</td>
<td>20th International Congress National College of Bacteriology</td>
<td>Bucaramanga, CO</td>
</tr>
<tr>
<td>Nov 18, 2022</td>
<td>Annual Meeting of the RBSLM</td>
<td>Brussels, BE</td>
</tr>
<tr>
<td>Nov 19, 2022</td>
<td>Inter-QC Topics: Measurement uncertainty and its usefulness in the laboratory</td>
<td>Quality Academics, online event</td>
</tr>
<tr>
<td>Nov 30, 2022</td>
<td>14th International Scientific Meeting: Implementation of metrological traceability in laboratory medicine: where we are and what is missing</td>
<td>Sesto San Giovanni Milan, IT</td>
</tr>
<tr>
<td>Dec 1 - 2, 2022</td>
<td>Journées de l’innovation en biologie (JIB 2022)</td>
<td>Hybrid event, Paris, FR</td>
</tr>
<tr>
<td>Dec 6 - 8, 2022</td>
<td>4th International Meeting in Clinical Chemistry &amp; Laboratory Medicine &amp; SSCC 8th Annual Meeting</td>
<td>Hybrid Event, Riyadh, Saudi Arabia</td>
</tr>
<tr>
<td>Jan 1 - Jul 31, 2023</td>
<td>Inter-QC Topics</td>
<td>Quality Academics, online event</td>
</tr>
<tr>
<td>Feb 9 - 10, 2023</td>
<td>Labquality Days 2023</td>
<td>Helsinki, FI</td>
</tr>
</tbody>
</table>
Khosrow ADELI
President

David KINNIBURGH
Secretary

Alexander HALLIASSOS
Treasurer

Joseph PASSARELLI
Corporate Representative

Regional Representatives

AB OKESINA
African Federation of Clinical Chemistry (AFCC)

A. HEDHILI
Arab Federation of Clinical Biology (AFCB)

S. SETHI
Asia-Pacific Fed for Clin Biochem and Lab Med (APFCB)

T. OBZEN
European Fed of Clin Chem and Lab Medicine (EFLM)

A.M. LENA
Latin-American Confederation of Clin Biochemistry (COLABIOCLI)

S. HILL

IFCC Divisions and C-CC Chairs

P. GILLERY (FR)
Scientific Division Chair

N. RIFAI (US)
Education and Management Division Chair

T. PILLAY (ZA)
Communications and Publications Division Chair

S. BERNARDINI (IT)
Emerging Technologies Division Chair

P. LAITINEN (FI)
Congresses and Conferences Committee Chair

IFCC Office Staff

(L-R) Silvia Cardinale, Paola Bramati, Silvia Colli Lanzi, Sofia Giardina, Smeralda Skenderaj
**Regional Federations**

- Arab Federation of Clinical Biology (AFCB)
- African Federation of Clinical Chemistry (AFCC)
- Asia-Pacific Federation for Clinical Biochemistry and Laboratory Medicine (APFCB)
- European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
- Latin America Confederation of Clinical Biochemistry (COLABIOLCU)
- North American Federation of Clinical Chemistry and Laboratory Medicine (NAFCC)

**Full Members**

- Albania (AL)
- Algeria (DZ)
- Argentina (AR)
- Australia and New Zealand (AU/NZ)
- Austria (AT)
- Belgium (BE)
- Bolivia (BO)
- Bosnia Herzegovina (BA)
- Brazil (BR)
- Bulgaria (BG)
- Canada (CA)
- Chile (CL)
- China (Beijing) (CN)
- China (Taipei) (TW)
- Colombia (CO)
- Croatia (HR)
- Cuba (CU)
- Cyprus (CY)
- Czech Republic (CZ)
- Denmark (DK)
- Dominican Republic (DO)
- Ecuador (EC)
- Egypt (EG)
- Estonia (EE)
- Ethiopia (ET)
- Finland (FI)
- France (FR)
- Georgia (GE)
- Germany (DE)
- Greece (GR)
- Guatemala (GT)
- Hong Kong (HK)
- Hungary (HU)
- Iceland (IS)
- India (IN)
- Indonesia (ID)
- Iran (IR)
- Iraq (IQ)
- Ireland (IE)
- Israel (IL)
- Italy (IT)
- Japan (JP)
- Jordan (JO)
- Kazakhstan (KZ)
- Kenya (KE)
- Korea (KR)
- Kosovo (KK)
- Latvia (LV)
- Lebanon (LB)
- Libya (LY)
- Lithuania (LT)
- Luxembourg (LU)
- Malawi (MW)
- Malaysia (MY)
- Mexico (MX)
- Montenegro (ME)
- Morocco (MA)
- Myanmar (MM)
- Nepal (NP)
- Netherlands (NL)
- Nigeria (NG)
- North Macedonia (MK)
- Norway (NO)
- Pakistan (PK)
- Palestine (PS)
- Panama (PA)
- Paraguay (PY)
- Peru (PE)
- Philippines (PH)
- Poland (PL)
- Portugal (PT)
- Romania (RO)
- Russia (RU)
- Saudi Arabia (SA)
- Serbia (SRB)
- Singapore (SG)
- Slovak Republic (SK)
- Slovenia (SI)
- South Africa (ZA)
- Spain (ES)
- Sri Lanka (LK)
- Sudan (SD)
- Sweden (SE)
- Switzerland (CH)
- Tunisia (TN)
- Turkey (TR)
- Ukraine (UA)
- United Kingdom (UK)
- United States (US)
- Uruguay (UY)
- Vietnam (VN)
- Zambia (ZM)
- Zimbabwe (ZW)

**Corporate Members**

- Abbott
- Agappe Diagnostics, Ltd.
- Arkray, Inc.
- Asahi Kasei Pharma Corp.
- Autobio Diagnostics Co., Ltd.
- BD Life Sciences – Preanalytical Systems
- Beckman Coulter, Inc.
- The Binding Site Group, Ltd.
- Bio-Rad Laboratories
- C.P.M. Diagnostic Research, SAS
- DiagSorin
- DiaSys Diagnostic Systems GmbH
- ET Healthcare Inc.
- Fujifilm Wako Pure Chemical Corporation
- Fujirebio Europe
- GenScript Biotech Corporation
- Gentian, AS
- Helena Biosciences Europe
- HemaStar Laboratories
- HyTest, Ltd.
- Immunodiagnostic Systems - IDS
- Instrumentation Laboratory
- Janssen微妙
- Luminar
- Medac Biotechnology Co., Ltd.
- MedicalSystem Biotechnology Co., Ltd.
- Medix Biochemica
- Megalab, JSC
- A. Menarini Diagnostics
- Mindray - Shenzhen Mindray Bio-Medical
- Nittobo Medical Co., Ltd.
- Nova Biomedical Corporation
- OneWorld Accuracy Collaboration
- Ortho-Clinical Diagnostics, Inc.
- PerkinElmer
- PDC Euro B.V.
- Quality Academics S.C.
- Radiometer Medical ApS
- Randox Laboratories, Ltd.
- Roche Diagnostics
- Sansure Biotech Inc.
- Sebia S.A.
- Sekisui Diagnostics Ltd.
- Sentinel CH SpA
- Shanghai Kehua Bio-Engineering Co., Ltd.
- Shenzhen YHLO Biotech Co., Ltd
- Siemens Healthcare Diagnostics
- Snibe Co., Ltd.
- Synlab
- Sysmex Europe, GmbH
- Technogenetics
- Thermo Fisher Scientific
- Tosoh Corporation
- Labor Dr. Wisplinghoff
- Wuhan Life Origin Biotech Joint Stock Co., Ltd.

**Affiliate Members**

- Botswana: Institute of Clinical Laboratory Professionals
- Brazil: Sociedade Brasileira de Patologia Clínica / Medicina Laboratorial (SBPC/ML)
- China: Lab Medicine Committee, China Association of Medical Equipment (LMC)
- Egypt: Egyptian Association of Healthcare Quality and Patient Safety
- France: French National Network of Accredited Laboratories of Medical Biology (LABAC)
- India: Association of Medical Biochemists of India (AMBI)
- Iran: Iranian Association of Clinical Laboratory Doctors (IACLD)
- Jordan: Society for Medical Technology & Laboratories (SMTL)
- Kazakhstan: Public Association - Federation of Laboratory Medicine (FLM)
- Mexico: Federación Nacional de Clínicos (CONAQUIC A.C.)
- Nepal: Nepalese Association for Clinical Chemistry (NACC)
- Philippines: Philippine Council for Quality Assurance in Clinical Laboratories (PCQACL)
- Romania: Order of the Biochemists, Biologists, Chemists in Romanian Health System (OBBCSSR)
- Serbia: Serbian Society for Clinical Laboratory Medicine and Science (SCLM)
- Spain: Andalusian Society for Clinical Analysis and Laboratory Medicine (SANAC)
- Spain: Asociación Española de Biopatología Médica - Medicina de Laboratorio (AEBM-ML)
- Asociación Española de Farmacéuticos Analistas (AEFA)
- Sri Lanka: College of Chemical Pathologists of Sri Lanka (CPCSL)
- Turkey: Society of Clinical Biochemistry Specialists (KBUD)
- Ukraine: Association for Quality Assurance of Laboratory Medicine (AQALM)
- United Arab Emirates: Genetic Diseases Association (UAEDGA)
Publisher
Communications and Publications
Division (CPD) of the IFCC

The Communications and Publications Division publishes ten editions of the e-News per year, including two double issues.

Editor
Katherina Psarra, MSc, PhD
Department of Immunology - Histocompatibility
Evangelismos Hospital, Athens, Greece
E-mail: enews@ifcc.org

Design & Production:

Circulation
The eNews is distributed to all IFCC members registered on-line to receive it and to all IFCC sponsors.

Deadlines for submissions
to the eNews
N° 1/2 – January/February: by mid January
N° 3 – March: by mid February
N° 4 – April: by mid March
N° 5 – May: by mid April
N° 6 – June: by mid May
N° 7/8 – July/August: by mid June
N° 9 – September: by mid August
N° 10 – October: by mid September
N° 11 – November: by mid October
N° 12 – December: by mid November

If you want to submit an article or advertisement to be published in the eNews, send it to:
Katherina Psarra, Editor, IFCC eNews
E-mail: enews@ifcc.org

Copyright © 2022 IFCC. All rights reserved.
Contents may not be reproduced without the prior permission of the Communications and Publications Division (CPD) of the IFCC.